Applied Therapeutics' Financial Performance Update
NEW YORK, Nov. 13, 2025 -- Applied Therapeutics, Inc. (NASDAQ: APLT), a clinical-stage biopharmaceutical company, announced its financial results for the third quarter that concluded on September 30, 2025. In this period, the company made significant progress in its clinical programs, especially for govorestat, a drug under development for treating serious rare diseases.
Regulatory Strategy and FDA Engagement
Update on CMT-SORD Meetings
Applied Therapeutics has been engaged in fruitful dialogue with the FDA regarding the development of govorestat aimed at treating Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD). Following a productive Type C meeting with the FDA, the company is dedicated to refining its regulatory strategy as it plans to submit a request for an additional meeting to discuss a potential Phase 3 trial.
Classic Galactosemia Discussions
The company has also scheduled a crucial meeting with the FDA to discuss the regulatory pathway for govorestat concerning the treatment of Classic Galactosemia. This discussion comes in the wake of a Complete Response Letter received previously and aims to align both parties on the necessary steps moving forward.
Development News on Govorestat
Recent Clinical Findings
New data released regarding govorestat highlights a significant achievement in treating PMM2-CDG, a severe genetic condition with high unmet medical need. Findings from a single-patient investigator-initiated study were presented at the 2025 ASHG Annual Meeting, showcasing a substantial reduction in sorbitol levels and improving clinical outcomes without adverse effects.
Commitment to Patients with Rare Diseases
Applied Therapeutics remains firm in its commitment to advancing research and development across its portfolio. The ongoing focus on govorestat is coupled with a robust safety profile seen in patients treated for over four years across various indications.
Corporate Developments
Leadership Transition
In a recent corporate update, it was announced that John Johnson would be stepping down from his role as Executive Chairman of the Board. Importantly, his decision did not stem from any disagreements concerning company strategies or operations. This leadership transition indicates a shift towards strengthening company governance as it moves forward in clinical trials and regulatory discussions.
Financial Results Overview
Performance Metrics
As of September 30, 2025, Applied Therapeutics reported cash and cash equivalents of $11.9 million, a significant decrease from $79.4 million at the end of 2024. The overall cash position reflects focused spending on clinical trials.
Research and development expenses were reported at $9.6 million, down from $14.8 million during the same period last year, indicating a strategic realignment in operational expenses. Administrative expenses also saw a decline to $8.2 million from $15.0 million, further highlighting the company's focus on cost management.
Net Loss Insights
The company reported a net loss of $19.0 million for the third quarter, translating to $0.13 per share, a notable improvement compared to a larger net loss of $68.6 million in the corresponding period of the previous year. This recovery reflects operational efficiencies and strategic prioritization of projects.
About Applied Therapeutics
Applied Therapeutics is known for its dedication to developing innovative treatments targeting validated biomarkers in rare diseases. The lead candidate, govorestat, represents a new approach in addressing metabolic disorders affecting the central nervous system.
The company encourages interested parties to learn more about its pioneering work by visiting their official website and connecting with them on social media.
Frequently Asked Questions
What are the latest updates on Applied Therapeutics' regulatory strategies?
Applied Therapeutics has engaged in discussions with the FDA regarding its lead candidate, govorestat, focusing on treatments for rare diseases.
How did the company perform financially in the third quarter?
The company reported a net loss of $19.0 million, showing an improvement over previous years, reflecting operational efficiencies.
What significant clinical findings were reported?
Recent discussions noted a substantial decrease in sorbitol levels in a patient receiving govorestat for the treatment of PMM2-CDG.
Is the company undergoing any leadership changes?
Yes, John Johnson has announced his resignation as Executive Chairman, which aims to facilitate a constructive governance transition.
What is govorestat's potential impact?
Govorestat holds promise for patients with rare metabolic diseases and has demonstrated a robust safety profile in clinical trials.
